MaaT Pharma SA (EPA: MAAT)

Market Cap	114.69M
Revenue (ttm)	2.57M
Net Income (ttm)	-24.14M
Shares Out	13.92M
EPS (ttm)	-2.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,175
Open	8.26
Previous Close	8.16
Day's Range	8.26 - 8.40
52-Week Range	6.30 - 9.90
Beta	0.20
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2024

About MaaT Pharma

MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and Maa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 60
• Stock Exchange: Euronext Paris
• Ticker Symbol: MAAT

Financial Performance

In 2023, MaaT Pharma's revenue was 2.23 million, an increase of 55.80% compared to the previous year's 1.43 million. Losses were -19.72 million, 43.8% more than in 2022.